Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Philadelphia, PA – Oncoceutics announced a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212.
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.
CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the therapeutic, and the rest of Vitaeris’s assets.
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
Shares of Gilead Sciences jumped in pre-market trading this weekend following reports that the company has been approached by U.K. pharma giant AstraZeneca regarding a potential merger.
When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.
Roche hopes to advance the development of its own nanopore sequencer, which would use a new approach combining electronic and biological components to sequence DNA quickly and at low cost.
Two years after Germany’s Fresenius Medical Care walked away from a 2017 $4.3 billion deal to acquire Akorn Pharmaceuticals, the company has filed for protection under U.S. bankruptcy laws as it attempts to restructure for a potential sale.
Xenotransplant company eGenesis snapped up a key manufacturing partner ICBiotec in order to vertically integrate its xeno-organ production capabilities.
Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.